This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Toretsky, J. A. Articles by Frantz, C. N. Search for Related Content PubMed PubMed Citation Articles by Toretsky, J. A. Articles by Frantz, C. N.

Phosphoinositide 3-Hydroxide Kinase Blockade Enhances Apoptosis in the Ewing’s Sarcoma Family of Tumors¹

Department of Pediatrics, University of Maryland, Baltimore, Maryland 21201

Ewing’s sarcoma family of tumors (ESFTs) affects patients between the ages of 3 and 40 years, with most cases occurring in the second decade of life. These tumors contain a characteristic translocation, t(11;22), that produces a unique fusion protein, EWS/FLI-1. EWS/FLI-1 transforms mouse fibroblasts; this transformation requires intact EWS and FLI-1 domains as well as the insulin-like growth factor-I receptor (IGF-IR). The IGF-IR is a well-described transmembrane tyrosine kinase receptor that modulates transformation, cell growth, and survival. IGF-IR survival signaling is mediated through the downstream activation of phosphoinositide 3-OH kinase (PI 3-K) and Akt. Apoptosis, programmed cell death, progresses from a central death signal to a caspase cascade, including activation of caspase-3. Because the IGF-IR has been shown to play a role in the transformation and growth of ESFTs, we wanted to determine the role of downstream molecules in the cellular response to doxorubicin treatment. Doxorubicin increased caspase-3 activity in two ESFT cell lines, TC-32 and TC-71. Concomitant treatment of the doxorubicin-treated cells with IGF-I reduced caspase-3 activity 8-fold in TC-32 and 4-fold in TC-71. To determine whether PI 3-K has a role in IGF-I-mediated survival in ESFTs, PI 3-K was then inhibited with wortmannin and LY294002. Doxorubicin treatment reduced cell number and enhanced apoptosis in PI 3-K inhibited cells compared with noninhibited cells. Akt, a serine/threonine kinase activated downstream of PI 3-K, was investigated to determine whether its constitutive activation would render ESFT cells more resistant to doxorubicin. A constitutively activated Akt was stably transfected into ESFT and those cells with high levels of expression demonstrated increased resistance to doxorubicin-induced caspase-3 activation. These results indicate that ESFT cell lines use an IGF-IR initiated signaling pathway through PI 3-K and Akt for survival when treated with doxorubicin.

This article has been cited by other articles:

				S. Y. Kim, J. A. Toretsky, D. Scher, and L. J. Helman The Role of IGF-1R in Pediatric Malignancies Oncologist, January 1, 2009; 14(1): 83 - 91. [Abstract] [Full Text] [PDF]

				K. Scotlandi, M. C. Manara, G. Nicoletti, P.-L. Lollini, S. Lukas, S. Benini, S. Croci, S. Perdichizzi, D. Zambelli, M. Serra, et al. Antitumor Activity of the Insulin-Like Growth Factor-I Receptor Kinase Inhibitor NVP-AEW541 in Musculoskeletal Tumors Cancer Res., May 1, 2005; 65(9): 3868 - 3876. [Abstract] [Full Text] [PDF]

				I. Gonzalez, E. J. Andreu, A. Panizo, S. Inoges, A. Fontalba, J. L. Fernandez-Luna, M. Gaboli, L. Sierrasesumaga, S. Martin-Algarra, J. Pardo, et al. Imatinib Inhibits Proliferation of Ewing Tumor Cells Mediated by the Stem Cell Factor/KIT Receptor Pathway, and Sensitizes Cells to Vincristine and Doxorubicin-Induced Apoptosis Clin. Cancer Res., January 15, 2004; 10(2): 751 - 761. [Abstract] [Full Text] [PDF]

				S. Eliazer, J. Spencer, D. Ye, E. Olson, and R. L. Ilaria Jr. Alteration of Mesodermal Cell Differentiation by EWS/FLI-1, the Oncogene Implicated in Ewing's Sarcoma Mol. Cell. Biol., January 15, 2003; 23(2): 482 - 492. [Abstract] [Full Text] [PDF]

				Q. Wang, N. Li, X. Wang, M. M. Kim, and B. M. Evers Augmentation of Sodium Butyrate-induced Apoptosis by Phosphatidylinositol 3'-Kinase Inhibition in the KM20 Human Colon Cancer Cell Line Clin. Cancer Res., June 1, 2002; 8(6): 1940 - 1947. [Abstract] [Full Text] [PDF]

				S. Benini, M. C. Manara, N. Baldini, V. Cerisano, Massimo Serra, M. Mercuri, P.-L. Lollini, P. Nanni, P. Picci, and K. Scotlandi Inhibition of Insulin-like Growth Factor I Receptor Increases the Antitumor Activity of Doxorubicin and Vincristine against Ewing's Sarcoma Cells Clin. Cancer Res., June 1, 2001; 7(6): 1790 - 1797. [Abstract] [Full Text] [PDF]